Sign in
Taking people in SpainPhase 4

Imaging brain amyloid and glucose use in people enrolled in the ALFA project

Studies how often amyloid brain scans are positive in adults at risk of Alzheimer's disease.

Key facts

Who runs it
Barcelonabeta Brain Research Center
Where
Barcelona, SpainSee the site
Registry title
Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and of glucose metabolism with 18F-FDG PET in individuals enrolled in the ALFA project
Status
Recruiting
Phase
Phase 4
People taking part
400 people, planned
Started
25 Jan 2025
Expected to end
30 Dec 2028
Type of study
Interventional
Record updated
13 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men and women already in the ALFA project (study 45-65 FPM/2012) who have normal thinking and memory scores. They will have brain PET scans to look for amyloid and measure glucose use.

Age
Records list a minimum age of 18 years; the study is for people enrolled in study 45-65 FPM/2012.
Sex
Men and women can join.
Disease stage
Normal thinking and memory at the start: MMSE 26 or higher, Verbal Semantic Fluency (animals) 12 or higher, and a score of 0 on the CDR scale.
Earlier treatment
Cannot have taken part in a study of an investigational medicine within 30 days before screening, or have had a radiopharmaceutical within 10 radioactive half-lives before the study drug.

Main reasons for not taking part

  • Memory or thinking problems at the start
  • Active drug or alcohol abuse
  • Pregnant or breast-feeding
  • Major psychiatric disorders such as major depression, schizophrenia or bipolar disorder
  • Cannot have an MRI scan (for example a pacemaker or metal implants)

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • To sign the study informed consent form approved by the corresponding authorities
  • Men and women enrolled in the STUDY 45-65 FPM/2012
  • Participants with a cerebral MRI (magnetic resonance imaging) not suggestive of radiological incidental findings constituting an exclusion criterion
  • Cognition within psychometric normal ranges: MMSE (Mini Mental State Examination ≥26 and Verbal Semantic Fluency (animals) ≥12) at baseline
  • Score of 0 in the CDR scale (Clinical Dementia Rating) at baseline
  • Good knowledge of Spanish or Catalan and being literate
  • Female participants should be post-menopausal or present a negative pregnancy test at the moment of PET realization

Who cannot take part

  • Active drug or alcohol abuse
  • Previous intolerance to PET studies or known hypersensitivity to 18F-Flutemetamol or 18F-FDG
  • Any contraindication to MRI acquisition, (i.e., metal implants) or phobia to performing the scan as determined by the onsite physician
  • Previous participation in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and/or administration of a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study
  • To present cognitive impairment at baseline
  • Presence of a pacemaker, aneurysm graft, artificial heart valves, auditory implants, cerebral shunts, metal fragments, or strange objects in the eyes, skin, or body that may contraindicate magnetic resonance imaging
  • Presence of clinically relevant psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) criteria: major depressive disorder, generalized anxiety disorder, schizophrenia and bipolar disorder
  • Individuals with visual and/or hearing impairment
  • History of encephalitis, ictus, or seizures excluding feverish convulsions during childhood
  • Severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumour (metastasis/brain cancer) as verified by magnetic resonance imaging (MRI)
  • Clinically relevant renal or hepatic insufficiency
  • Any other clinically significant condition that may jeopardize the study or be dangerous for the participant
  • Being pregnant or breast-feeding

Where in Spain

  • Barcelonabeta Brain Research CenterBarcelona, SpainTaking people

About the trial

What the trial wants to find out

To determine the prevalence and progression of positive 18F-Flutemetamol scans in individuals recruited in the ALFA project

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and of glucose metabolism with 18F-FDG PET in individuals enrolled in the ALFA project
Plain-language title
Imaging brain amyloid and glucose use in people enrolled in the ALFA projectGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
13 May 2026